Motus GI's Pure-Vu EVS Gastro Used in First Procedure

By Chris Wack

Motus GI Holdings said its Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance.

The medical technology company said the case was completed by a gastroenterologist and associate professor of medicine at the University of Minnesota.

The Pure-Vu EVS Gastro, which received clearance from the Food and Drug Administration in late October, is intended for patients who suffer from upper gastrointestinal bleeding. The Pure-Vu EVS Gastro targets blood, blood clots and other debris in the upper GI tract.

Motus GI shares were up 43% at $5.11 in premarket trading.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

11-10-23 0837ET